The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study
Abstract
OBJECTIVE: The aim was to evaluate the efficacy, safety and tolerability of rivastigmine capsules in patients diagnosed with probable vascular dementia (VaD). METHODS: VantagE (Vascular Dementia trial studying Exelon) was a 24-week, multicentre, double-blind study. VaD patients aged 50-85 years were randomized to rivastigmine capsules (3-12 mg/day) or placebo. Efficacy assessments included global and cognitive performances, activities of daily living and neuropsychiatric symptoms. Adverse events were recorded. Additional exploratory analyses determined whether heterogeneity in pathologies and symptoms extended to differential treatment effects. TRIAL REGISTRATION: NCT00099216. RESULTS: 710 patients were randomized. Rivastigmine demonstrated superiority over placebo on three measures of cognitive performance (Vascular Dementia Assessment Scale, Alzheimer's Disease Assessment Scale cognitive subscale, Mini-Mental State Examination; all p< or = 0.05, intent-to-treat population [ITT]), but not other outcomes. Predominant adverse events were nausea and vomiting. Exploratory analyses indicated that older patients (> or =75 years old), assumed more likely to also have Alzheimer's disease (AD) pathology, demonstrated significant cognitive responses to rivastigmine and a safety profile similar to that seen in AD patients. Younger patients, assumed less likely to have concomitant AD pathology, showed no efficacy response and were associated with slight elevations of blood pressure, cerebrovascular accidents and mortality. Rivastigmine-placebo differences in patients with, versus those without, medial temporal atrophy (also suggestive of concomitant AD) showed a numerical difference similar to that seen between the older versus younger patients, but did not attain statistical significance. CONCLUSION: Consistent with trials evaluating other cholinesterase inhibitors, rivastigmine did not provide consistent efficacy in probable VaD. The efficacy apparent on cognitive outcomes was derived from effects in older patients likely to have concomitant Alzheimer pathology. This is supportive of an existing argument that the putative cholinergic deficit in VaD reflects the presence of concomitant Alzheimer pathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the single trial of rivastigmine, there was a significant benefit on the cognition without significant global benefit or benefit on activities of daily living. 265”
From Vascular Cognitive Impairment (2017) · cites this paper as [265]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
The Global Deterioration Scale for assessment of primary degenerative dementia
(1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.9.1136 · Cited by 4,986
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationA new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Scheltens, P., Leys, D., Barkhof, F., Huglo, D., Weinstein, H. C., Vermersch, P., Kuiper, M., Steinling, M., Wolters, E. C., & Valk, J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.10.967 · Cited by 1,784
Self-citationRivastigmine for Dementia Associated with Parkinson's Disease
Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., De Deyn, P. P., Durif, F., Kulisevsky, J., van Laar, T., Lees, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041470 · Cited by 1,223
Self-citation
Research works printed but not linked: 8
- Heyman A, 1998, Consortium to Establish a Registry for Alzheimer's disease. Neurology, 51, 159
- Roman GC, 1993, Report of the NINDS-AIREN International Workshop. Neurology, 43, 250
- Gottfries CG, 1994, Dementia, 5, 163
- Erkinjuntti T, 2000, J Neural Transm Suppl, 59, 23
- Folstein MF, 1975, A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 12, 189
- Ferris SH, 1999, Alzheimer Dis Assoc Disord, 13, S140
- Corey-Bloom J, 1998, Int J Geriatr Psychopharmacol, 1, 55
- 10.1016/s1474-4422(07)70195-3 · DOI · Paper page
Cited by
Pantoni, L. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70104-6 · Cited by 3,405
O'Brien, J. T., & Thomas, A. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00463-8 · Cited by 1,136
Review: Cerebral microvascular pathology in ageing and neurodegeneration
Brown, W. R., & Thore, C. R. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01139.x · Cited by 749
Post-stroke dementia – a comprehensive review
Mijajlović, M. D., Pavlović, A., Brainin, M., Heiss, W.-D., Quinn, T. J., Ihle-Hansen, H. B., Hermann, D. M., Assayag, E. B., Richard, E., Thiel, A., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0779-7 · Cited by 693
“Acetylcholinesterase inhibitors and memantine may have a beneficial effect on cognition in patients with mild to moderate vascular dementia in general [97], but evidence for both general improvement are limited.”
BackgroundPost-stroke cognitive impairment: epidemiology, mechanisms and management.
(2014) · PubMed Central · doi:10.3978/j.issn.2305-5839.2014.08.05 · Cited by 680
“And the trials on rivastigmine suggested the effect on executive function in VCI (92,93).”
BackgroundDichgans, M., & Leys, D. (2017) · Circulation Research · doi:10.1161/circresaha.116.308426 · Cited by 581
Lin, J. S., O’Connor, E., Rossom, R. C., Perdue, L. A., & Eckstrom, E. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-9-201311050-00730 · Cited by 410
“…al, 1998* (144) Forette et al, 1999* (145) Karaman et al, 2005* (146) McKeith et al, 2000* (147) Rösler et al, 1999* (149) Winblad et al, 2007 (141) Ballard et al, 2008 (138) Feldman et al, 2007 (139) Mok et al, 2007 (140) Subtotal: I2 = 44.6%; P = 0.062 Memantine Orgogozo et al, 2002* (155)…”
InfluentialO’Brien, J. T., Holmes, C., Jones, M., Jones, R., Livingston, G., McKeith, I., Mittler, P., Passmore, P., Ritchie, C., Robinson, L., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116680924 · Cited by 354
Patnode, C. D., Perdue, L. A., Rossom, R. C., Rushkin, M. C., Redmond, N., Thomas, R. G., & Lin, J. S. (2020) · JAMA · doi:10.1001/jama.2019.22258 · Cited by 309
Battle, C. E., Abdul‐Rahim, A. H., Shenkin, S. D., Hewitt, J., & Quinn, T. J. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013306.pub2 · Cited by 226
Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions
Carrarini, C., Russo, M., Dono, F., Barbone, F., Rispoli, M. G., Ferri, L., Pietro, M. D., Digiovanni, A., Ajdinaj, P., Speranza, R., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.644317 · Cited by 192
“Indeed, a strict correlation among neuropsychiatric symptoms (NPS), especially aggressiveness, and tau pathology, rather than amyloid, is commonly reported in AD patients (12, 14, 15).”
BackgroundInfluentialQuinn, T. J., Richard, E., Teuschl, Y., Gattringer, T., Hafdi, M., O'Brien, J. T., Merriman, N., Gillebert, C., Huygelier, H., Verdelho, A., et al. (2021) · European Journal of Neurology · doi:10.1111/ene.15068 · Cited by 182
Quinn, T. J., Richard, E., Teuschl, Y., Gattringer, T., Hafdi, M., O'Brien, J. T., Merriman, N. A., Gillebert, C. R., Huygelier, H., Verdelho, A., et al. (2021) · European Stroke Journal · doi:10.1177/23969873211042192 · Cited by 166
O’Brien, J. T., & Burns, A. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110387547 · Cited by 164
“In a randomized double-blind placebo-controlled trial of rivastigmine capsules, significant benefit was found on V-ADAS-Cog, ADAS-Cog and MMSE, but not other outcomes (Ballard et al., 2008).”
BackgroundRomán, G. C., Salloway, S., Black, S. E., Royall, D. R., DeCarli, C., Weiner, M. W., Moline, M., Kumar, D., Schindler, R., & Posner, H. (2010) · Stroke · doi:10.1161/strokeaha.109.570077 · Cited by 161
Knight, R., Khondoker, M., Magill, N., Stewart, R., & Landau, S. (2018) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000486546 · Cited by 161
Ischemic brain injury in cerebral amyloid angiopathy
Reijmer, Y. D., van Veluw, S. J., & Greenberg, S. M. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.88 · Cited by 158
Kim, D. H., Brown, R. T., Ding, E. L., Kiel, D. P., & Berry, S. D. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03450.x · Cited by 154
Mixed dementia: A review of the evidence
Custodio, N., Montesinos, R., Lira, D., Herrera-Pérez, E., Bardales, Y., & Valeriano-Lorenzo, L. (2017) · Dementia & Neuropsychologia · doi:10.1590/1980-57642016dn11-040005 · Cited by 148
Khan, A., Kalaria, R. N., Corbett, A., & Ballard, C. G. (2016) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988716654987 · Cited by 145
“The size of benefit has not been considered sufficient to include VaD within the treatment license for any of the available cholinesterase inhibitors.(224,225) There is a strong indication from these trials that there is more substantial benefit in individuals with mixed VaD and AD.”
BackgroundSelf-citationStaekenborg, S. S., Su, T., van Straaten, E. C. W., Lane, R. M., Scheltens, P., Barkhof, F., & van der Flier, W. M. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.187500 · Cited by 144
“phase III, prospective, randomised, double-blind, placebocontrolled clinical trial of the effects of rivastigmine in patients with mild to moderate VaD.(13) Trial inclusion criteria included both fulfilment of the DSM-IV diagnostic criteria for VaD and fulfilment of the NINDS-AIREN criteria for VaD according to centra…”
MethodSelf-citationVascular Cognitive Impairment: Disease Mechanisms and Therapeutic Implications
Levine, D. A., & Langa, K. M. (2011) · Neurotherapeutics · doi:10.1007/s13311-011-0047-z · Cited by 141
“In addition, the rivastigmine group had higher rates of nausea and vomiting than the placebo group [82].”
BackgroundInfluentialJia, J., Wei, C., Liang, J., Zhou, A., Zuo, X., Song, H., Wu, L., Chen, X., Chen, S., Zhang, J., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.04.010 · Cited by 131
Herrmann, N., Lanctôt, K. L., & Hogan, D. B. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt201 · Cited by 126
“Th e effi cacy apparent on the cognitive outcomes was seen only in older patients who were more likely to have concomitant AD pathology, supporting the argument that the putative cholinergic defi cit seen in VaD refl ects the presence of concomitant AD pathology [28].”
MethodResultRivastigmine for vascular cognitive impairment
Birks, J., McGuinness, B., & Craig, D. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004744.pub3 · Cited by 121
Wang, S., Yang, H., Zhang, J., Zhang, B., Liu, T., Gan, L., & Zheng, J. (2016) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1337-0 · Cited by 90
“shown that drugs that are usually used to treat Alzheimer’s disease, such as the cholinesterase inhibitors donepezil, galantamine, and rivastigmine, and the noncompetitive N-methyl-D-aspartate receptor antagonist memantine, were associated with neurological benefits in patients with post-stroke cognitive impairment [3…”
BackgroundIşık, A. T., Soysal, P., Stubbs, B., Solmi, M., Basso, C., Maggi, S., Schofield, P., Veronese, N., & Mueller, C. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15415 · Cited by 88
“Initial data on safety came from randomized controlled trials conducted in subjects with good CV health.(50,51) In recent years, a number of open-label and observational studies examining cohorts more similar to real-world clinical populations have been published.”
MethodRabins, P. V., Rovner, B. W., Rummans, T. A., Schneider, L. S. S., & Tariot, P. N. (2017) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.15106 · Cited by 87
Caruso, P., Signori, R., & Moretti, R. (2019) · Vascular Health and Risk Management · doi:10.2147/vhrm.s190470 · Cited by 80
“Finally, the possible side-effects of those drugs must be taken into account.(213,214)”
BackgroundNon-invasive brain stimulation to enhance cognitive rehabilitation after stroke
Draaisma, L. R., Wessel, M. J., & Hummel, F. C. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.06.047 · Cited by 78
Lee, A. Y. (2011) · Chonnam Medical Journal · doi:10.4068/cmj.2011.47.2.66 · Cited by 78
“Rivastigmine (Exelon) was studied in a randomized, placebo-controlled trial of 710 patients and it was superior to placebo on the ADAS-Cog score as a primary efficacy measure, except in younger (age 50-75 years) patients.(35) Memantine (Ebixa) was studied for the treatment of VaD in two large trials and both trials co…”
MethodPharmacological prevention and treatment of vascular dementia: Approaches and perspectives
Baskys, A., & Cheng, J. (2012) · Experimental Gerontology · doi:10.1016/j.exger.2012.07.002 · Cited by 76
Caramelli, P., Marinho, V., Laks, J., Coletta, M. V. D., Stella, F., Camargos, E. F., Smid, J., Barbosa, B. J. A. P., Schilling, L. P., Balthazar, M. L. F., et al. (2022) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2022-s106pt · Cited by 66
Therapeutic Strategies and Drug Development for Vascular Cognitive Impairment
Smith, E. E., Cieślak, A., Barber, P. A., Chen, J. Y., Chen, Y., Donnini, I., Edwards, J. D., Frayne, R., Field, T. S., Hegedus, J., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005568 · Cited by 61
Clinical Trials of New Drugs for Vascular Cognitive Impairment and Vascular Dementia
Linh, T. T. D., Hsieh, Y., Huang, L., & Hu, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911067 · Cited by 59
“The effectiveness of rivastigmine on cognitive outcomes was determined through an examination of its effects on older patients likely to have concomitant Alzheimer’s pathology [79].”
BackgroundEfficacy of Cholinesterase Inhibitors in Vascular Dementia: An Updated Meta-Analysis
Chen, Y., Zhang, J., Wang, Y., Yuan, J., & Hu, W. (2016) · European Neurology · doi:10.1159/000444253 · Cited by 55
Soysal, P., Işık, A. T., Stubbs, B., Solmi, M., Volpe, M., Luchini, C., D’Onofrio, G., Pilotto, A., Manzato, E., Sergi, G., et al. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-313660 · Cited by 51
“Randomized controlled trials reporting data on weight loss Nine RCTs were included in our meta-analysis reporting, among nutritional parameters, only data about subjects with weight loss in the treated and placebo group during follow-up.(40-48) The median”
MethodLiu, H., & Jin, B. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.249228 · Cited by 49
“The network meta-analysis of ADAS-cog score changes on cognition included 10 RCTs (Erkinjuntti et al., 2002; Orgogozo et al., 2002; Wilcock et al., 2002; Black et al., 2003; Wilkinson et al., 2003; Auchus et al., 2007; Ballard et al., 2008; Dichgans et al., 2008; Narasimhalu et al., 2010; Román et al., 2010), which in…”
BackgroundMethodInfluentialUse of Cholinesterase Inhibitors in Non-Alzheimer’s Dementias
Noufi, P. E., Khoury, R., Jeyakumar, S., & Grossberg, G. T. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00685-6 · Cited by 47
Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype
Lane, R. M., & He, Y. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.12.005 · Cited by 39
“In the absence of synaptic ACh deficits, enhanced cholinergic neurotransmission induced by synaptic AChE inhibition induces tolerability and safety issues and no cognitive improvement [383].”
BackgroundInfluentialSelf-citationLane, R. M., & Darreh‐Shori, T. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142268 · Cited by 35
Self-citationDang, C., Wang, Q., Zhuang, Y., Li, Q., Feng, L., Xiong, Y., & Lu, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1451032 · Cited by 33
Neurotechnologies as tools for cognitive rehabilitation in stroke patients
Draaisma, L. R., Wessel, M. J., & Hummel, F. C. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1820324 · Cited by 33
Sheffrin, M., Miao, Y., Boscardin, W. J., & Steinman, M. A. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13511 · Cited by 31
Shi, X., Ren, G., Cui, Y., & Xu, Z. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220120112301 · Cited by 30
Lane, R. M., & He, Y. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.01.050 · Cited by 30
“This has proven to be the case in trials of donepezil, galantamine and rivastigmine in patients with probable vascular dementia (that is, trials that attempted to recruit patients with dementia that was due solely to cerebrovascular pathology) [93,94].”
BackgroundResultInfluentialSelf-citationTreatment of Vascular Cognitive Impairment
Ritter, A. R., & Pillai, J. A. (2015) · Current Treatment Options in Neurology · doi:10.1007/s11940-015-0367-0 · Cited by 30
Multi-Infarct Dementia: A Historical Perspective
McKay, E., & Counts, S. (2017) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000470836 · Cited by 28
Kim, Y., Kang, D. W., Kim, G. H., Kim, K. W., Kim, H. J., Na, S., Park, K. H., Park, Y. H., Byeon, G., Suh, J., et al. (2025) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2025.24.1.1 · Cited by 26
Systematic Review of Sex‐Specific Reporting of Data: Cholinesterase Inhibitor Example
Mehta, N., Rodrigues, C., Lamba, M., Wu, W., Bronskill, S. E., Herrmann, N., Gill, S. S., Chan, A., Masón, R., Day, S., et al. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15020 · Cited by 26
Zekry, D., & Gold, G. (2010) · Drugs & Aging · doi:10.2165/11538250-000000000-00000 · Cited by 26
Vascular Cognitive Impairment and Post-Stroke Cognitive Deficits
Shim, H. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0418-4 · Cited by 24
“This study showed improvements in cognition, but no statistically significant effects on global functioning, behavior, or activities of daily living [20].”
BackgroundPrescripciones inconvenientes en el tratamiento del paciente con deterioro cognitivo
Bayón, A. R., & Sampedro, F. G. (2012) · Neurología · doi:10.1016/j.nrl.2012.05.004 · Cited by 22
Salvadori, E., Poggesi, A., Donnini, I., Rinnoci, V., Chiti, G., Squitieri, M., Tudisco, L., Fierini, F., Melone, A., Pescini, F., et al. (2019) · Aging Clinical and Experimental Research · doi:10.1007/s40520-019-01229-z · Cited by 22
Salvadori, E., Poggesi, A., Donnini, I., Rinnoci, V., Chiti, G., Squitieri, M., Tudisco, L., Fierini, F., Melone, A., Pescini, F., et al. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00852-8 · Cited by 22
Driving and dementia: a clinician's guide
Wilson, S., & Pinner, G. (2013) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.111.009555 · Cited by 22
Genetic Associations of Autopsy-Confirmed Vascular Dementia Subtypes
Jones, E. L., Kalaria, R. N., Sharp, S. I., O'Brien, J. T., Francis, P. T., & Ballard, C. G. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000327171 · Cited by 22
Self-citationWang, P., Wang, Y., Feng, T., Zhao, X., Zhou, Y., Wang, Y., Shi, W., & Ju, Y. (2012) · BMC Neurology · doi:10.1186/1471-2377-12-88 · Cited by 22
“However, previous studies showed that cholinesterase inhibitors had controversial roles in treating vascular diseases [17-19].”
ResultLennon, M. J., & Sachdev, P. S. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02331-3 · Cited by 19
Ahuja, M., Siddhpuria, S., Karimi, A., Lewis, K., Wong, E. K. C., Lee, J., Reppas‐Rindlisbacher, C. E., Sood, E., Gabor, C., & Patterson, C. (2023) · Age and Ageing · doi:10.1093/ageing/afad205 · Cited by 18
O'Brien, J. T., & Thomas, A. J. (2017) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.15104 · Cited by 18
Current and Emerging Therapeutic Approaches for Vascular Cognitive Impairment and Dementia
Goodall, L., Lennon, M. J., Sachdev, P. S., Gorelick, P. B., Kovacic, J. C., & Samaras, K. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.1502 · Cited by 17
Ravi, R., Das, S., Hakami, T. M., M., P. B., & Pushparajan, L. (2025) · Stroke Research and Treatment · doi:10.1155/srat/6893801 · Cited by 15
“The results of the studies on the use of rivastigmine in patients with PSCI suggest that it may have some bene fi ts in improving executive function, but there is little evidence to support its use for improving overall cognitive function or activities of daily living [33, 35].”
Caramelli, P., Marinho, V., Laks, J., Coletta, M. V. D., Stella, F., Camargos, E. F., Smid, J., Barbosa, B. J. A. P., Schilling, L. P., Balthazar, M. L. F., et al. (2022) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2022-s106en · Cited by 15
Pharmacological Treatment of Dementia
Hahn, S. J., & Paik, N. (2015) · Brain & Neurorehabilitation · doi:10.12786/bn.2015.8.1.19 · Cited by 13
Cognitive impairments in cerebrovascular disease: What is between health and dementia?
Emelin, А. Y. (2015) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2015-1-94-98 · Cited by 13
Inappropriate treatments for patients with cognitive decline
Bayón, A. R., & Sampedro, F. G. (2014) · Neurología (English Edition) · doi:10.1016/j.nrleng.2012.05.009 · Cited by 13
Butler, R., & Radhakrishnan, R. (2012) · PubMed · Cited by 13
Gupta, S., Fiertag, O., & Warner, J. P. (2009) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.107.003558 · Cited by 12
Park, K. W., Kim, E. J., Han, H. J., Shim, Y. S., Kwon, J. C., Ku, B. D., Park, K. H., Yi, H.-A., Kim, K. K., Yang, D. W., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182123 · Cited by 12
Supporting self-management in early dementia: a contribution towards ‘living well’?
Cheffey, J., Hill, L., Roberts, G. A., & Marlow, R. (2013) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.112.011023 · Cited by 12
Turning the Spotlight to Cholinergic Pharmacotherapy of the Human Language System
Dávila, G., Torres‐Prioris, M. J., López-Barroso, D., & Berthier, M. L. (2023) · CNS Drugs · doi:10.1007/s40263-023-01017-4 · Cited by 11
COGNITIVE DISORDERS AND THEIR TREATMENT IN HYPERTENSION
Захаров, В. В., Васильевна, В. Н., & Parfenov, V. A. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-0-6-12 · Cited by 11
Imaging, Genetic, and Pathological Features of Vascular Dementia
Yang, X., Chen, C., Wang, A., Li, C., & Cheng, G. (2023) · European Neurology · doi:10.1159/000531088 · Cited by 11
Pharmacological Treatment of Post-stroke Cognitive Deficits
Berthier, M. L., Dávila, G., Edelkraut, L., López-Barroso, D., Torres‐Prioris, M. J., & Tubío-Ordónez, J. (2020) · Springer eBooks · doi:10.1007/978-3-030-49586-2_19 · Cited by 11
Management of Cognitive Impairment After Stroke
Jerdi, S. A., Aleyadeh, R., & Imam, Y. Z. B. (2020) · Current Treatment Options in Neurology · doi:10.1007/s11940-020-00627-3 · Cited by 10
Лобзин, С. В., Sokolova, M. G., & Nalkin, S. A. (2017) · HERALD of North-Western State Medical University named after I I Mechnikov · doi:10.17816/mechnikov20179453-58 · Cited by 9
Yan, L., Xu, K., Liu, C., Feng, Y., Guo, J., Hou, L., Feng, Y., Yang, M., Gong, Q., Qin, D., et al. (2024) · Advanced Materials · doi:10.1002/adma.202412843 · Cited by 7
Liu, J., Gong, J., Xu, J., Fang, M., Su, M., Li, W., Wu, Y., Hui, Y., & He, Y. L. (2023) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2023/9021546 · Cited by 7
Self-citationCognition enhancers for the treatment of dementia
Malek, N., & Greene, J. (2014) · Scottish Medical Journal · doi:10.1177/0036933014561948 · Cited by 7
Custodio, N., Montesinos, R., Alva‐Díaz, C., Mejía-Rojas, K. K., Becerra‐Becerra, Y., & Lira, D. (2016) · Revista de Neuro-Psiquiatría · doi:10.20453/rnp.v79i3.2921 · Cited by 7
Is It Possible to Treat Vascular Dementia?
Zekry, D. (2009) · Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences · doi:10.1159/000197888 · Cited by 7
Alvarado, A. J. M., Brito, C. C., Román, G. C., Gareri, P., Aguilar-Navarro, S. G., Sandoval, J. L. R., Calleja-Castillo, J. M., Velázquez, C., Ardila, G. P., Merino, M. S. C., et al. (2017) · Journal of Neurology and Neuroscience · doi:10.21767/2171-6625.1000224 · Cited by 6
Thöne-Otto, A. I. T., Ackermann, H., Benke, T., Bezold, R., Hildebrandt, H., Meiling, C., Müller, S., Nyffeler, T., Schoof-Tams, K., & Wallesch, C. (2020) · Zeitschrift für Neuropsychologie · doi:10.1024/1016-264x/a000298 · Cited by 5
Presenting Turkish Inappropriate Medication Use in the Elderly (TIME) Criteria Set in Turkish
Bahat, G., İlhan, B., Erdoğan, T., Halil, M. G., Savaş, S., Ülger, Z., Akyüz, F., Bilge, A. K., Çakır, S., Demirkan, K., et al. (2021) · European Journal of Geriatrics and Gerontology · doi:10.4274/ejgg.galenos.2021.6-6 · Cited by 5
Poststroke cognitive impairment: diagnosis and treatment
Golovacheva, V. A., & Александровна, Г. А. (2018) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2018-2-88-94 · Cited by 5
Fan, C. F., & Romero, J. R. (2016) · Internal Medicine Review · doi:10.18103/imr.v2i11.265 · Cited by 4
“There are a few available therapies for improved dementia symptoms, including memantine (an NMDA receptor, improvement in cognition),[86] acetylcholinesterase inhibitors such as galantamine,[87] donepezil[88] (tested in patients with a genetic form of CSVD, cerebral autosomal dominant arteriopathy with subcortical inf…”
BackgroundProposal of Evidence-based East-West Integrative Medicine Manual for Vascular Dementia
Kim, B., Jo, H.-G., Kang, H., Choi, S.-Y., Song, M.-Y., Sul, J.-U., & Leem, J. (2019) · 대한한의학회지 · doi:10.13048/jkm.19005 · Cited by 4
Vascular Dementia and Vascular Cognitive Impairment
Budson, A. E., & Solomon, P. R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28661-9.00006-8 · Cited by 4
Iranmanesh, F., Shafiee, K., & Farzan, A. (2020) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.22062/jkmu.2020.90614 · Cited by 3
Meta-Analysis of Naoxintong Capsule for Patients with Vascular Dementia
Li, L., Zheng, Y., Bao, J., Zhao, Y., Zhang, Q., Li, W., & Wu, M. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/5000948 · Cited by 3
Grover, S., Avasthi, A., & Gupta, G. (2016) · Journal of Geriatric Mental Health · doi:10.4103/2348-9995.181921 · Cited by 3
Emelin, А. Y., & Lobzin, V. Y. (2020) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2020-4-131-136 · Cited by 2
What Can Person-Centred Care in Dementia Learn from the Recovery Movement?
Hill, L., Roberts, G. A., & Perkins, R. E. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.018 · Cited by 2
Costa, Y. S., Lim, A. S. P., Thorpe, K. E., Mitchell, S., Masellis, M., Lam, B. Y. B., Black, S., & Boulos, M. I. (2022) · Sleep Medicine · doi:10.1016/j.sleep.2022.05.396 · Cited by 2
Drug repurposing for vascular dementia: overview and current developments
Mucke, H. A. (2016) · Future Neurology · doi:10.2217/fnl-2016-0001 · Cited by 2
Vascular dementia and vascular cognitive impairment
Budson, A. E., & Solomon, P. R. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-3597-8.00006-8 · Cited by 2
Vascular Dementia and Parkinsonism
Silveira‐Moriyama, L., Barbosa, E. R., Caramelli, P., Zijlmans, J. C. M., & Lees, A. J. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6365-7_12 · Cited by 2
Psychosocial Interventions in Dementia
Kiridoshi, A. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.019 · Cited by 2
Review of Treatment for Late-Life Depression
Hay, K., Stageman, W., & Allan, C. L. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.021 · Cited by 2
Metadata
- Authors
- Ballard, C., Sauter, M., Scheltens, P., He, Y., Barkhof, F., van Straaten, E. C. W., van der Flier, W. M., Hsu, C., Wu, S., & Lane, R.
- Affiliations
- King's College London (GB)
- Westmoreland Neurology, Greensburg, Pennsylvania, USA
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Novartis (United States) (US)
- Department of Neurology, Radiology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands
- Novartis (Switzerland) (CH)
- Corresponding author
- Ballard, C.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2008-07-30
- Volume
- 24
- Issue
- 9
- Pages
- 2561-2574
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2150693120
- Cited by
- 147
- References
- 57
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 7 · 2020: 41 · 2019: 6 · 2018: 4 · 2017: 12 · 2016: 11 · 2015: 9 · 2014: 5 · 2013: 9 · 2012: 5
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- rivastigmine, vascular dementia, cholinesterase inhibitors, cognitive performance, Alzheimer's disease pathology, medial temporal lobe atrophy, age differences in treatment response, adverse events, neuropsychiatric symptoms, activities of daily living
- MeSH terms
- Rivastigmine, Administration, Oral, Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Male, Middle Aged, Placebos, Prospective Studies, Dementia, Vascular, Treatment Outcome, Neuroprotective Agents, Phenylcarbamates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.